Drug Delivery to the Ischemic Brain
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Cerebral ischemia occurs when blood flow to the brain is insufficient to meet metabolic demand. This can result from cerebral artery occlusion that interrupts blood flow, limits CNS supply of oxygen and glucose, and causes an infarction/ischemic stroke. Ischemia initiates a cascade of molecular events inneurons and cerebrovascular endothelial cells including energy depletion, dissipation of ion gradients, calcium overload, excitotoxicity, oxidative stress, and accumulation of ions and fluid. Blood-brain barrier (BBB) disruption is associated with cerebral ischemia and leads to vasogenic edema, a primary cause of stroke-associated mortality. To date, only a single drug has received US Food and Drug Administration (FDA) approval for acute ischemic stroke treatment, recombinant tissue plasminogen activator (rt-PA). While rt-PA therapy restores perfusion to ischemic brain, considerable tissue damage occurs when cerebral blood flow is re-established. Therefore, there is a critical need for novel therapeutic approaches that can “rescue” salvageable brain tissue and/or protect BBB integrity during ischemic stroke. One class of drugs that may enable neural cell rescue following cerebral ischemia/reperfusion injury is the HMG-CoA reductase inhibitors (i.e., statins). Understanding potential CNS drug delivery pathways for statins is critical to their utility in ischemic stroke. Here, we review molecular pathways associated with cerebral ischemia and novel approaches for delivering drugs to treat ischemic disease. Specifically, we discuss utility of endogenous BBB drug uptake transporters such as organic anion transporting polypeptides (OATPs/Oatps) and nanotechnology-based carriers for optimization of CNS drug delivery. Overall, this chapter highlights state-of-the-art technologies that may improve pharmacotherapy of cerebral ischemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial formation of reactive oxygen species
Turrens, J. F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.049478 · Cited by 5,084
Thresholds in cerebral ischemia - the ischemic penumbra.
Astrup, J., Siesjö, B. K., & Symon, L. (1981) · Stroke · doi:10.1161/01.str.12.6.723 · Cited by 2,820
Biodegradable nanoparticles for drug delivery and targeting
Hans, M. L., & Lowman, A. M. (2002) · Current Opinion in Solid State and Materials Science · doi:10.1016/s1359-0286(02)00117-1 · Cited by 1,324 · cited 4×
“The chemical nature of PEG allows liposomes to circulate in the bloodstream longer, avoiding collection by the RES in the liver and spleen (Hans & Lowman, 2002; Pinzon-Daza et al., 2013; Xie et al., 2012).”
BackgroundInfluentialNanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 1×
“Apolipoprotein E (ApoE), found in blood plasma, has been shown to adsorb on the surface of the polysorbate 20-, 40-, 60-, or 80-coated nanoparticles and likely mimics LDL, allowing receptor binding (Kreuter, 2001).”
BackgroundGuzy, R. D., & Schumacker, P. T. (2006) · Experimental Physiology · doi:10.1113/expphysiol.2006.033506 · Cited by 881 · cited 1×
“This paradoxical increase of superoxide despite low oxygen concentrations has been well described (Guzy & Schumacker, 2006; Murphy, 2009).”
BackgroundThe Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., & Amidon, G. L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012126301290 · Cited by 858
Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy
Shishehbor, M. H., Aviles, R. J., Brennan, M.-L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Penn, M. S., Sprecher, D. L., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1675 · Cited by 464 · cited 1×
“In addition to these preclinical studies, statin treatment has been shown to reduce cerebral expression of oxidative stress markers (i.e., nitrotyrosine and F2-isoprostanes) in clinical investigations (Davignon, Jacob, & Mason, 2004; Shishehbor et al., 2003).”
BackgroundSchreibelt, G., Kooij, G., Reijerkerk, A., van Doorn, R., Gringhuis, S. I., van der Pol, S., Weksler, B. B., Romero, I. A., Couraud, P., Piontek, J., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8329com · Cited by 347 · cited 1×
“Production of ROS and subsequent oxidative stress alters expression and molecular organization of critical tight junction proteins claudin-5 and occludin at the BBB, leading to increased paracellular solute leak (Lochhead et al., 2010; Schreibelt et al., 2007).”
BackgroundMitochondrial reactive oxygen species and Ca 2+ signaling
Camello-Almaraz, C., Gomez-Pinilla, P. J., Pozo, M. J., & Camello, P. J. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00217.2006 · Cited by 336
Lochhead, J. J., McCaffrey, G., Quigley, C. E., Finch, J., DeMarco, K. M., Nametz, N., & Davis, T. P. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.29 · Cited by 334 · cited 4×
“Specifically, TEMPOL prevents breakage of disulfide bonds on occludin thereby blocking disruption of occludin oligomeric assemblies and subsequent blood-to-brain leak of circulating solutes (Lochhead et al., 2010).”
BackgroundInfluential
Cited by
Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy
Tian, T., Zhang, H.-X., He, C.-P., Fan, S., Zhu, Y.-L., Qi, C., Huang, N.-P., Xiao, Z.-D., Lu, Z.-H., Tannous, B. A., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.012 · Cited by 1,154
Abdullahi, W., Tripathi, D., & Ronaldson, P. T. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00095.2018 · Cited by 613
Self-citationGlucose transporters in brain in health and disease
Koepsell, H. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02441-x · Cited by 558
“The arterial occlusion causes irreversible structural damages in a core region and changes in a surrounding area called penumbra that may be reversible [17, 237, 398].”
BackgroundIschemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells
Belov Kirdajova, D., Kriska, J., Tureckova, J., & Anderova, M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00051 · Cited by 428
Ronaldson, P. T., & Davis, T. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20951995 · Cited by 392
“glutathione), DNA fragmentation, and induction of mitochondrial failure.(70) Peroxynitrite can also induce cellular injury due to its ability to nitrosylate tyrosine residues, thereby inducing modifications to critical proteins.”
BackgroundSelf-citationGlucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery
Patching, S. G. (2017) · Molecular Neurobiology · doi:10.1007/s12035-015-9672-6 · Cited by 361
Drug delivery systems for programmed and on-demand release
Davoodi, P., Lee, L. Y., Xu, Q., Sunil, V., Sun, Y., Soh, S., & Wang, C.-H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.002 · Cited by 353
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
“Gradually, brain edema, BBB damage, and nerve tissue damage result in associated disorders including neuronal cell death [260–262].”
Exosome-mediated targeted delivery of miR-210 for angiogenic therapy after cerebral ischemia in mice
Zhang, H., Wu, J., Wu, J., Fan, Q., Zhou, J., Wu, J., Liu, S., Zang, J., Ye, J., Xiao, M., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0461-7 · Cited by 281
Focusing on claudin-5: A promising candidate in the regulation of BBB to treat ischemic stroke
Lv, J., Hu, W., Yang, Z., Li, T., Jiang, S., Ma, Z., Chen, F., & Yang, Y. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.12.001 · Cited by 148
Metadata
- Authors
- Thompson, B. J., & Ronaldson, P. T.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2014
- Volume
- 71
- Pages
- 165-202
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W2404708375
- Cited by
- 107
- References
- 20
- FWCI
- 23.81
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.